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What is known on this topic?
What this paper adds?
• Patients with lung cancer are at increased risk of developing venous thromboembolism (VTE), significantly affecting morbidity and mortality.
• Fractal dimension of blood clots is significantly higher in patients with lung cancer compared to healthy controls, suggesting an abnormal clot structure.
• There are currently no reliable markers which accurately quantify pathological clot structure.
• Patients with extensive (stage III & IV) lung cancer had significantly higher d f as compared to those with limited disease (stages I & II).
• Fractal dimension (d f ) is a new technique previously demonstrated to quantify clot microstructure, shown to be associated with changes observed by scanning electron microscopy (SEM).
• Changes in d f were associated with similar changes in SEM images, reaffirming the link between incipient and mature clot structure.
Abstract
Background: Venous thromboembolism (VTE) is common in cancer patients, and is the second commonest cause of death associated with the disease. Patients with chronic inflammation, such as cancer, have been shown to have pathological clot structures with modulated mechanical properties. Fractal dimension (d f ) is a new technique which has been shown to act as a marker of the microstructure and mechanical properties of blood clots, and can be performed more readily than current methods such as scanning electron microscopy (SEM).
Methods: This study compares d f in 87 patients with newly diagnosed lung cancer to 47 matchedcontrols, in addition to analysis based on stage of disease. Results were compared with conventional markers of coagulation, fibrinolysis and SEM images.
Results: Significantly increased d f was observed in lung cancer patients compared with controls.
Significantly increased d f was observed in patients with extensive (stage 3/4) compared with limited disease (stage 1/2) (p<0.05), whilst conventional markers failed to distinguish between these groups. The relationship between d f of the incipient clot and mature clot microstructure was
Introduction
Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolus (PE) is a common phenomenon affecting 6.5 million people worldwide annually (1,2).
The incidence is higher in people with cancer who account for 18% of all cases of VTE (3), with an estimated 4 to 20% of cancer patients developing VTE during the course of their disease (4) .
VTE contributes significantly to morbidity and mortality in patients with cancer, in whom it remains the second commonest cause of death (5) . Risk factors for VTE include advancing age, metastatic burden, surgery and chemotherapy (3) . Cancers are also known to vary in thrombogenicity with histological type and primary tumour site. Compared with the general population, lung cancer confers a 22-fold increased risk of VTE, second only to haematological malignancies (6) .
Despite the well-documented incidence of VTE in patients with cancer, little is known on the effects of differences in global coagulation on the structure of clots formed, and if these are pathologically abnormal compared to healthy individuals. Factors that increase the thrombogenicity in malignancy result from release of tumour procoagulants such as tissue factor (TF), microparticles and factor VIII (7) (8) (9) (10) . In addition, chronic inflammation has long been associated with cancer (11) (12) (13) , having an important role in modulating the tumour microenvironment and its impact on systemic processes, including proliferation and migration (12) . It has also been suggested that as cancers metastasize and grow, inflammatory processes may be increased (13) , which may have greater impact on systemic processes such as haemostasis. Previous studies on patients with inflammatory disorders and vascular disease have demonstrated the development of pathological clots of a dense, highly polymerised and less porous microstructure (14) , which may alter mechanical properties of the clot (15) (16) (17) (18) . Further ! 5! studies have suggested that fibrinolytic properties may also be reduced in blood clots in with abnormal structure (19, 20) . It is therefore likely that patients with cancer also form pathological clots with similar arrangement and resulting structural properties, which may be modulated by stage of disease and accompanying chronic inflammation. There is however, currently no method of investigating or quantifying the link between chronic inflammation and its global effect on processes such as haemostasis.
Attempts have been undertaken using viscoelastic techniques to investigate clot formation in patients with cancer. Several studies using thromboelastography (TEG) and rotational thromboelastometry (ROTEM) have suggested its use in predicting thromboembolic complications in cancer patients, (21) (22) (23) whilst others have demonstrated no differences (24, 25) .
However, conflicting results on whether these techniques can be used to accurately assess changes in global coagulation in patients with cancer and the relatively small populations of patients with mixed primary tumour sites, limit their clinical utility. A larger study of ROTEM parameters demonstrated that patients with lung cancer had decreased clotting time and increased maximum clot firmness than healthy controls (26) . These parameters were further altered in patients with extensive lung cancer compared to those with limited disease and in patients who went on to develop VTE, but cannot be used to identify differences in coagulation depending on stage of disease (26) . In combination, these studies suggest that not only do patients with cancer form clots faster, but that physical clot properties may also be different in these patients, leading to pathological clot formation. which are all calculated from the gel point (GP) (27) (28) (29) (30) . In contrast to standard coagulation assays, this technique uses unadulterated whole blood and is measured immediately at the bedside during real-time formation of the clot. In addition, structure of the early clot, as quantified by d f , has been established as providing a template for the mature clot when analysed based on viscoelastic and imaging data (31, 32) . We have previously shown that d f quantified the microstructure of the incipient clot in normal and anticoagulated blood in a sensitive and highly reproducible manner (30, 32) , and that this is important in quantifying the underlying pathological effect on clot structure (33) . Similarly, increased d f , has been demonstrated in patients with inflammatory vascular disorders (34, 35) , correlating with scanning electron microscopy (SEM) images of the mature blood clot. Measurement of global coagulation and resulting clot structure in using this biomarker may therefore be a means of investigating and quantifying the effect of chronic inflammation on haemostasis. As far as we are aware, this technique has not been applied to the study of blood clot formation in patients with malignancy.
We hypothesised that blood from lung cancer patients could have modulated mechanical properties at its GP compared with healthy controls, given the increased inflammation in these patients. In order to test this hypothesis, the present study was designed to investigate whether d f was significantly different in patients with lung cancer compared to appropriately matched controls, and if changes varied with stage of lung cancer. In order to investigate whether high d f values predict pathological abnormalities in mature clot structure, SEM imaging was also performed.
Materials and Methods

Patients
We undertook a prospective, observational study of consecutive patients with histologically or cytologically confirmed primary lung cancer diagnosed by the Swansea Multi-Disciplinary Lung Cancer Clinic. Exclusion criteria were as follows:
)
Previous history of cancer Given the high proportion of patients with smoking history, we undertook a preliminary study to compare levels of d f in smoking and non-smoking controls. In order to address the effect of comorbidities, we compared patients with limited lung cancer (stages I & II) and those with extensive disease (stages III & IV), as the prevalence of co-morbidities appeared similar in both groups. A number of patients were on taking therapy for hypertension, hyperlipidaemia and prophylactic doses of aspirin (75mg), representative of the population of the study locality. These patients were not excluded as it was thought that aspirin therapy would favour the null hypothesis.
Venesection
Blood was taken from the antecubital vein via a Vacutainer® Needle following diagnosis and before any specific therapy was offered. The first 3-5 mls were discarded as waste. Whole venous blood was transferred immediately for rheometric analysis. Further samples were transferred into vacuum-sealed tubes containing sodium citrate (3.2%) or K 2 EDTA (Greiner Bio-one, Stonehouse, UK) for measurement of standard markers of coagulation and fibrinolysis.
Rheometric analysis
The biomarkers (T GP , G`G P & d f ) which are the focus of this study are obtained from the measurement of viscoelastic properties at of the gel point obtained from clotting blood (27, 29, 30, 32) . A 6.6 ml aliquot of whole unadulterated venous blood was loaded into a doublegap concentric cylinder measuring geometry of a TA Instruments AR-G2 (TA Instruments, New
Castle, DE, USA) controlled-stress rheometer (at 37°C ± 0.1ºC) in a near patient setting. All rheometric sampling was carried out by members of the research team who were appropriately trained and experienced in rheometric analysis. In order to eliminate bias and enhance accuracy of measurement, data was anonymised and reviewed independently by three haemorheologists blinded to the sample origin, and the mean used for further analysis.
Computational analysis
In order to investigate the relatively small change in d f and the previously reported increase in fibrin mass of the mature clot (33), computational analysis was carried out. Previously, a numerical technique has been used to generate random fractal aggregates where the fractal dimension is fixed a priori is presented (37, 38) . The algorithm utilizes the box-counting measure of the fractal dimension to determine the number of hypercubes required to encompass the aggregate, on a set of length scales, over which the structure is deemed to be fractal. At each length scale the number of required hypercubes are randomly chosen and importantly linked using a simple random walk in the embedding dimension. This late step ensures connectivity of the random fractal aggregate on all considered length scales. The algorithm is highly efficient and overcomes the limitations on the achievable magnitude of the fractal dimension encountered by alternative techniques. This provides a visual illustration of clot structure, based on the d f values measured on whole blood, and allows the corresponding fibrin mass to be calculated.
Coagulation screen
Standard time based kinetic markers of clot initiation, propagation and fibrinolysis were carried out. PT, APTT and Clauss fibrinogen were measured using a Sysmex CA1500 analyser within 2 hrs of collection. All reagents were obtained from Siemens, (Frimley, UK).
Thrombin Generation
Thrombin generation was measured using the Thrombin Generation Assay (TGA, Technoclone Diagnostics, Vienna, Austria). 40µL of citrated plasma was dispensed into a 96 well ELISA plate, prewarmed to 37ºC (NUNC F16 maxisorp black fluorescence plates, Pathway Diagnostics, Dorking, UK). Ten µL of TF was added to a final concentration of 5pM followed by 50µL of fluorogenic substrate 1mM Z-G-G-R-AMC (Technoclone Diagnostics, Vienna, Austria). Plates were loaded into the fluorogenic plate reader TECAN infinite F200 pro (Labtech International,
Uckfield, UK) and read every 60seconds for 1 hour. TGA® software was used to calculate individual thrombin generation curves.
Factor VIII Analysis
Factor VIII was performed as one-stage factor assays on the ACL TOP 500 according to manufacturer's instructions using Instrumentation laboratory calibration plasma, quality control material and factor deficient substrate plasma (Instrumentation Laboratory, Warrington, UK).
Fibrinolytic Markers
PAI-1 antigen was measured using an ELISA assay performed according to manufacturer's instructions (Hyphen Biomed, Quadratech, Epsom, UK). D-Dimer analysis was carried out using Latex immunoturbidimetric assay Hemosil HS D-dimer (Instrumentation Laboratory, Warrington, UK). The D-dimer assay was performed on an ACL TOP 500 (Instrumentation Laboratory, Warrington, UK).
Microparticle assay
ELISA bio-immunoassay for MP-TF in plasma was performed according to manufacturers instructions using calibration and positive and negative controls (Hyphen Biomed, Quadratech, Epsom, UK).
Scanning electron microscopy
SEM samples were prepared by allowing 12µl of whole blood to clot for 15 minutes at 37 o C.
Resulting clots were washed with cacodylate buffer and fixed with gluteraldehyde, before pointcritical dehydration with ethanol (30-100%) and hexamethyldisilazane (Sigma Aldrich, UK).
Samples were coated with gold palladium, imaged using a Hitachi Ultra-high resolution FE-SEM S-4800, and fibre width of randomly selected regions calculated as previously described (39) .
Statistical analysis
Power calculations were performed to achieve the primary aim of identifying differences in d f between a healthy individuals and a pilot group of patients with lung cancer. Parametric data are reported as mean (±SD) unless otherwise stated and compared using two-sample t-tests. Pearson correlation was undertaken to explore associations between d f and standard markers of coagulation where significant differences were identified between those with limited compared to extensive disease. Statistical analysis was performed using Minitab version 15 software (Havertown, PA) and deemed significant when p<0.05.
Results
Rheometric Analysis (d f )
Mean d f was 1.73±0.04 in healthy individuals and comparable with levels reported in our previous study of healthy individuals from the same locality (30) . There was no significant difference in d f between healthy non-smokers (1.73 ± 0.04) and healthy smokers (1.74 ± 0.03, p=0.10), therefore both groups were combined to make a larger group of healthy controls (n= 47).
Lung cancer patients had a significantly higher 
Computational analysis
In patients with lung cancer, relatively small changes in d f related to large increases in fibrin mass, as calculated by computation analysis. Fibrin mass was on average 150% greater than controls and up to 215% in those with extensive disease. In the patient with the highest d f , this equated to over 700% fibrin mass of healthy controls. Computational models illustrated that highly dense clot structures are generated at the highest d f values identified in this study, compared to those of controls ( Figure 2 ). These images clearly show a significant difference in the structures of the clots formed over this range, the high density of red (nodes) in the 1.91 image indicates an area of increased cross connectivity, creating a very strong clot, in contrast to that of the 1.73 image where there are significantly fewer dense (red) areas.
Laboratory markers
All healthy controls were within normal reference ranges (Table 3) . No significant differences were observed in coagulation screen between controls and patients with lung cancer (PT: 10. 
Scanning electron microscopy of mature clot structure
Clots formed from blood from patients with extensive lung cancer were denser and had a more an increased risk of VTE (1-5), but also that pathological clots formed are of abnormally dense structure, particularly in those with extensive disease. These findings were also confirmed by images generated by SEM, demonstrating clots of highly dense, polymerised structures in patients
In contrast to rheometric data, we observed no significant differences in standard time-based kinetic markers of coagulation between patient groups and controls. These findings were also consistent in patients with extensive compared to limited disease. Whilst patients had significantly higher levels of platelets and fibrinogen compared to controls, it is noteworthy that all results fell within local normal ranges. Further markers of thrombus initiation (FVIII, TF-
MPs), propagation (TGA) or fibrinolysis (D-dimer), did also not differentiate between patients
with limited compared to extensive lung cancer. However, results obtained were markedly elevated in patients with cancer, particularly those with extensive disease, despite remaining within normal ranges. Whilst there was no difference in Factor VIII levels between limited and extensive disease, a number of patients had levels near or above the normal range. This is consistent with previous publications (7) (8) (9) (10) , in which patients with malignancies found that increased Factor VIII was associated with a 14% cumulative probability of VTE (10), and may also be indicative of the chronic inflammation present in these patients. D-dimer has also been described to be increased in patients with cancer (40), but our current data suggest that it cannot be used to differentiate between local and extensive disease. In contrast to the elevated levels of both Factor VIII and D-dimer described, d f did differentiate between stages of disease, emphasizing its specificity in this population.
PAI-1 was significantly higher in those with extensive lung cancer, suggesting increased suppression of fibrinolytic activity in this group. This is in keeping with previous studies, which have identified increased PAI-1 in various malignancies (41) (42) (43) , a decrease in fibrinolytic efficiency in clots from patients with gastrointestinal cancer (45) . Furthermore, PAI-1 significantly correlate with d f in patients with extensive lung cancer, all be it a weak correlation.
This may suggest that d f takes into account suppression of the fibrinolytic system, in combination with quantifying the microstructural arrangement of the clot. In our previous study, d f was shown to be an accurate marker of fibrinolysis and anticoagulation therapy (30, 33) , and as such may have potential to not only quantify thrombogenicity, but also to guide and improve anticoagulation therapy. These findings suggest that manipulation of the clot structure may be an effective target in therapeutic intervention, given the pathological differences in clot structure observed.
The present study provides additional evidence to support previous studies demonstrating that the clot structure, quantified by d f , acts as a template predicting the structure of the mature clot demonstrated in SEM images. Blood clots from patients with lung cancer who had progressively higher levels of d f , were found on SEM to be composed of progressively thinner fibrin fibres that displayed increased numbers of branching points creating a denser, less porous structure than those from healthy individuals. Patients with extensive disease produced clots of the highest density with small porous spaces, suggested to be representative of the increased inflammation present in those with highest tumour burden, as previously described (12, 13) . This is consistent with previous publications demonstrating that increased d f translates to highly polymerised, dense clots in patients with inflammatory vascular disease (34, 35) . there are only a handful of red areas, representing relatively few areas of fibrin cross connectivity.
At 1.91 the clot is comprised of mainly red nodal areas, representing multiple areas of fibrin connectivity, which would translate to clots with highly elastic properties. Consequently these clots will mechanically stronger and less susceptible to breakdown. The rheological findings, in combination with SEM images and computation analysis, support previous studies identifying clots of abnormally dense structure in patients with inflammatory disorders (14, 15, 19, 34, 35) , which may increase resistance of these clots to fibrinolysis (16) (17) (18) . This supports previous reports that not only does chronic inflammation in cancer impact upon tumour progression, but also has an effect on systemic process such as haemostasis (11) (12) (13) , which may have an indirect effect on efficiency of the fibrinolytic system.
Our preliminary study comparing d f in healthy smokers and non-smokers showed that there was no significant difference between the two groups. This is in keeping with a recent epidemiological study suggesting that only heavy smoking conveyed an increased VTE risk (46) . This suggests that the changes in d f we observed between lung cancer patients and controls are due to increased thrombogenicity of malignancy, and not smoking per se. Furthermore, this study did not find significant differences in measures of viscoelasticity or standard measures of coagulation between patients with different lung cancer cell types, in contrast to a previous report non-small cell tumours are more thrombogenic than small cell tumours (47).
There are several advantages to using d f in this regard: firstly, it is a rapid and convenient assay on 
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